SCHEMBL1725976

SCHEMBL1725976

NS(=O)(=O)c1cccc(Cl)c1C(=O)O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.47
CA1 P00915 6/20 0.47
CA2 P00918 6/20 0.47
CA12 O43570 4/20 0.47
CA9 Q16790 4/20 0.47
CA7 P43166 2/20 0.47
CA14 Q9ULX7 2/20 0.47
CA3 P07451 1/20 0.47
CA4 P22748 1/20 0.47
CA6 P23280 1/20 0.47
CA5A P35218 1/20 0.47
CA13 Q8N1Q1 1/20 0.47
CISD1 Q9NZ45 1/20 0.47
CA5B Q9Y2D0 1/20 0.47
ALDH1A1 P00352 1/20 0.45
PTGES2 Q9H7Z7 4/20 0.44
LMNA P02545 1/20 0.43
CDK2 P24941 1/20 0.43
PBRM1 Q86U86 1/20 0.42
DPP4 P27487 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9161266 0.81 ALDH1A1 (0.45) ALDH1A1LMNAPBRM1DPP4TSHR
SCHEMBL1804843 0.81 CA1 (0.61) CA1CA2CA12CA9CA7
SCHEMBL9620280 0.80 CA1 (0.57) KMT2ACA1CA2CA12CA9
SCHEMBL1804840 0.79 CDK2 (0.44) CA1CA2CA12CA9CA7
SCHEMBL3528844 0.79 CA1 (0.49) CA1CA2CA12CA9CA7
SCHEMBL11872448 0.79 CA1 (0.55) CA1CA2CA12CA9CA7
SCHEMBL11218763 0.79 CA1 (0.49) CA1CA2CA12CA9CA7
SCHEMBL742940 0.78 PTGES2 (0.64) KMT2ACA1CA2CA12CA9
SCHEMBL29578190 0.78 PTGES2 (0.64) KMT2ACA1CA2CA12CA9
SCHEMBL3862961 0.78 TSHR (0.55) CA1CA2CA12CA9CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9187438-B2 Derivatives of benzothiazines, preparation thereof and application thereof as drugs PIERRE FABRE MEDICAMENT (FR) 2015-11-17 US disclosed
EP-2403840-B1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS PF MEDICAMENT (FR) 2014-05-14 EP disclosed
CN-102341379-A Derivatives of benzothiazines, preparation thereof and application thereof as drugs PF MEDICAMENT 2012-02-01 CN disclosed
EP-2403840-A1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS Pierre Fabre Médicament (FR) 2012-01-11 EP disclosed
US-20110319326-A1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS PIERRE FABRE MEDICAMENT (FR) 2011-12-29 US disclosed
WO-2010100139-A1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS PIERRE FABRE MEDICAMENT (FR) 2010-09-10 WO disclosed
CN-101711250-A Benzenesulfonamide methylene substituted mercapto pyrrolidine carbapenem derivatives KBP BIOMEDICAL CO LTD 2010-05-19 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110319326-A1 DERIVATIVES OF BENZOTHIAZINES, PREPARATION THEREOF AND APPLICATION THEREOF AS DRUGS HSD11B1, CYP11B1, HSD17B11 KMT2A 2151/4885CA1 1084/4885CA2 1946/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.